Preserving Cardiac Health in the Breast Cancer Patient Treated with Anthracyclines

  • Neville Davidson


Improved management and increasingly aggressive treatment have resulted in more women living with and surviving breast cancer. For these women, an increasingly important issue is the potentially negative effects of cancer treatment on quality of life, such as treatment-related cardiac dysfunction. In addition to ensuring the best results against the cancer, there is now a growing onus on oncologists to manage these adverse treatment effects. Anthracyclines represent one of the most effective and widely used agents for breast cancer, but are associated with well-recognised, dose-related cardiotoxicity. Strategies aimed at maximising anthracycline efficacy while minimising cardiotoxicity include: screening patients for cardiovascular risk factors and the institution of proactive treatment when possible [e.g. stopping smoking, use of angiotensin-converting enzyme (ACE) inhibitors, etc.], active monitoring of cardiac function, limiting the lifetime cumulative dose, and/or utilising a less cardiotoxic liposomal preparation.


Breast Cancer Left Ventricular Ejection Fraction Metastatic Breast Cancer Liposomal Doxorubicin Cardiac Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    World Cancer Report 2008. World Health Organisation. International Agency Research on Cancer, 2008.Google Scholar
  2. 2.
    Cancer Research UK. CancerStats Key Facts on Breast Cancer. Available from [Accessed December 2009].
  3. 3.
    Yau TK. Cardiotoxicity after adjuvant anthracycline-based chemotherapy and radiotherapy for breast cancer. J HK Coll Radiol 2005;8:26–29.Google Scholar
  4. 4.
    Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.PubMedCrossRefGoogle Scholar
  5. 5.
    Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer: therapy and cardiovascular injury. Am J Coll Cardiol 2007;50:1435–1441.CrossRefGoogle Scholar
  6. 6.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–2247.PubMedCrossRefGoogle Scholar
  7. 7.
    Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7:13–19.PubMedGoogle Scholar
  8. 8.
    Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589–600.PubMedCrossRefGoogle Scholar
  9. 9.
    Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14–25.PubMedCrossRefGoogle Scholar
  10. 10.
    Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007;7:61–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Vergely C, Delemasure S, Cottin Y, et al. Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab 2007;35:1–7.Google Scholar
  12. 12.
    Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009;20:816–827.PubMedCrossRefGoogle Scholar
  13. 13.
    Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900–2902.PubMedCrossRefGoogle Scholar
  14. 14.
    Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879.PubMedCrossRefGoogle Scholar
  15. 15.
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.Google Scholar
  16. 16.
    Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502–3508.PubMedGoogle Scholar
  17. 17.
    Ewer MS, Martin FJ, Henderson IC, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31(Suppl 13):161–181.PubMedCrossRefGoogle Scholar
  18. 18.
    Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann Intern Med 1982;96:133–139.PubMedGoogle Scholar
  19. 19.
    van Dalen EC, van der Pal HJ, Caron HN, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006;4:CD005008.Google Scholar
  20. 20.
    Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745–749.PubMedGoogle Scholar
  21. 21.
    Goethals I, De Winter O, De Bondt P, et al. The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol 2002;13:1331–1339.PubMedCrossRefGoogle Scholar
  22. 22.
    Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365–375.PubMedCrossRefGoogle Scholar
  23. 23.
    Slamon DJ, Leylan-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.PubMedCrossRefGoogle Scholar
  24. 24.
    Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiotoxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicentre trial. Cancer 2003;97:40–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001;12:1067–1073.PubMedCrossRefGoogle Scholar
  26. 26.
    Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713–2721.PubMedGoogle Scholar
  27. 27.
    Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699–709.PubMedCrossRefGoogle Scholar
  28. 28.
    Dranitsaris G, Rayson D, Vincent M, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;107:443–450.PubMedCrossRefGoogle Scholar
  29. 29.
    Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Goodwin PJ. Weight gain in early-stage breast cancer: where do we go from here? J Clin Oncol 2001;19:2367–2369.PubMedGoogle Scholar
  31. 31.
    Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006;33:2–14.PubMedCrossRefGoogle Scholar
  32. 32.
    Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity – what does modern cardiology offer? Support Care Cancer 2008;16:437–445.PubMedCrossRefGoogle Scholar
  33. 33.
    Harris L, Batist G, Belt R, et al; for the TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25–36.PubMedCrossRefGoogle Scholar
  34. 34.
    O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–449.PubMedCrossRefGoogle Scholar
  35. 35.
    Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444–1454.PubMedGoogle Scholar
  36. 36.
    Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318–326.PubMedCrossRefGoogle Scholar
  37. 37.
    Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008;26:1–3.CrossRefGoogle Scholar
  38. 38.
    Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.PubMedCrossRefGoogle Scholar
  39. 39.
    Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–828.PubMedCrossRefGoogle Scholar
  40. 40.
    López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:1454–1470.PubMedCrossRefGoogle Scholar
  41. 41.
    Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004;2:251–266.PubMedGoogle Scholar
  42. 42.
    van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;2:CD003917.Google Scholar
  43. 43.
    Giotta F, Lorusso V, Maiello E, et al. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol 2007;18(Suppl 6):vi66–vi69.PubMedCrossRefGoogle Scholar
  44. 44.
    Batist G, Harris L, Azarnia N, et al. Improved anti-tumour response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-cancer Drugs 2006;17:587–595.PubMedCrossRefGoogle Scholar
  45. 45.
    Chan S, Davidson N, Juozaityte E, et al; on behalf of the Myocet Study Group. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527–1534.PubMedCrossRefGoogle Scholar
  46. 46.
    van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006;4:CD005006.Google Scholar
  47. 47.
    Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773–2778.PubMedCrossRefGoogle Scholar
  48. 48.
    Cortes J, Di Cosimo S, Climent MA, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 2009;15:307–314.PubMedCrossRefGoogle Scholar
  49. 49.
    Schmid P, Krocker J, Jehn C, et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol 2005;16:1624–1631.PubMedCrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Department of Oncology ResearchBroomfield HospitalEssexUK

Personalised recommendations